Stan Miele, Thomas Polasek, Susanna Mantovani, Sara M Camp, Joe G N Garcia
Introduction: Human and preclinical studies have highlighted eNAMPT (extracellular nicotinamide phosphoribosyl transferase) as a druggable TLR4 ligand and DAMP involved in the pathobiology of diverse inflammatory, fibrotic and cancer disorders. This Phase 1 study assesses the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the humanized eNAMPT-neutralizing ALT-100 mAb as a strategy to address the unmet need for effective anti-inflammatory, anti-fibrotic therapeutics.
Materials and methods: Healthy male and female volunteers received a single intravenous ALT-100 dose (0.1, 0.4, 1.0, 4.0 mg/kg, n=24 dosed) or placebo (n=12 dosed) with 120-day monitoring (injection site, vital signs, hematology, coagulation, blood chemistry, urinalysis, PK/PD parameters, plasma biomarkers, anti-drug antibodies).
Results: ALT-100 was well tolerated at all doses without clinically significant changes in local tolerability, vital signs, or laboratory safety parameters. Treatment-emergent adverse events (TEAEs) were unrelated to ALT-100 mAb dose (mild/moderate in severity), and AEs were transient and resolved without clinical sequelae. There were no serious adverse events (SAEs). Median ALT-100 mAb plasma levels peaked at 0.62 hour after dosing (all doses). The mean maximum mAb plasma concentration (Cmax) and mAb elimination half-life (T1/2) all increased in a dose-related manner between 0.4 mg/kg (17 days) and 4 mg/kg (27 days).
Conclusions: Single intravenous ALT-100 mAb doses are well tolerated in healthy participants with dose proportional PK and elimination half-life.
{"title":"Safety, Tolerability and Pharmacokinetics of the eNAMPT-Neutralizing ALT-100 Mab in Healthy Volunteers.","authors":"Stan Miele, Thomas Polasek, Susanna Mantovani, Sara M Camp, Joe G N Garcia","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Human and preclinical studies have highlighted eNAMPT (extracellular nicotinamide phosphoribosyl transferase) as a druggable TLR4 ligand and DAMP involved in the pathobiology of diverse inflammatory, fibrotic and cancer disorders. This Phase 1 study assesses the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the humanized eNAMPT-neutralizing ALT-100 mAb as a strategy to address the unmet need for effective anti-inflammatory, anti-fibrotic therapeutics.</p><p><strong>Materials and methods: </strong>Healthy male and female volunteers received a single intravenous ALT-100 dose (0.1, 0.4, 1.0, 4.0 mg/kg, n=24 dosed) or placebo (n=12 dosed) with 120-day monitoring (injection site, vital signs, hematology, coagulation, blood chemistry, urinalysis, PK/PD parameters, plasma biomarkers, anti-drug antibodies).</p><p><strong>Results: </strong>ALT-100 was well tolerated at all doses without clinically significant changes in local tolerability, vital signs, or laboratory safety parameters. Treatment-emergent adverse events (TEAEs) were unrelated to ALT-100 mAb dose (mild/moderate in severity), and AEs were transient and resolved without clinical sequelae. There were no serious adverse events (SAEs). Median ALT-100 mAb plasma levels peaked at 0.62 hour after dosing (all doses). The mean maximum mAb plasma concentration (C<sub>max</sub>) and mAb elimination half-life (T1/2) all increased in a dose-related manner between 0.4 mg/kg (17 days) and 4 mg/kg (27 days).</p><p><strong>Conclusions: </strong>Single intravenous ALT-100 mAb doses are well tolerated in healthy participants with dose proportional PK and elimination half-life.</p>","PeriodicalId":520420,"journal":{"name":"Journal of clinical research and clinical trials","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11823460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号